Gardasil® - The new HPV vaccine: The right product, the right time? A commentary

Joel Lexchin, Neil Arya, Sonal Singh

Research output: Contribution to journalArticle

Abstract

The federal and provincial governments have undertaken a universal immunization program to protect school-aged girls against cervical cancer using the new human papillomavirus vaccine Gardasil®. While the vaccine appears to be effective and safe, there are a number of important unanswered questions regarding it and the effects of the immunization program. Here we briefly review key literature about the vaccine and then use the Erickson criteria, which offer an evidence basis for decision-making regarding national immunization strategies, to evaluate whether the program is congruent with sound public health policy. Our analysis of the national decision to recommend and fund a vaccination program using Gardasil® raises significant questions about the basis for this program.

Original languageEnglish (US)
Pages (from-to)26-36
Number of pages11
JournalHealthcare Policy
Volume5
Issue number4
StatePublished - May 2010

Fingerprint

Papillomavirus Vaccines
Immunization Programs
Vaccines
State Government
Federal Government
Decision Support Techniques
Financial Management
Public Policy
Health Policy
Uterine Cervical Neoplasms
Immunization
Decision Making
Vaccination
Public Health
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18

ASJC Scopus subject areas

  • Health Policy
  • Public Health, Environmental and Occupational Health

Cite this

Gardasil® - The new HPV vaccine : The right product, the right time? A commentary. / Lexchin, Joel; Arya, Neil; Singh, Sonal.

In: Healthcare Policy, Vol. 5, No. 4, 05.2010, p. 26-36.

Research output: Contribution to journalArticle

Lexchin, J, Arya, N & Singh, S 2010, 'Gardasil® - The new HPV vaccine: The right product, the right time? A commentary', Healthcare Policy, vol. 5, no. 4, pp. 26-36.
Lexchin, Joel ; Arya, Neil ; Singh, Sonal. / Gardasil® - The new HPV vaccine : The right product, the right time? A commentary. In: Healthcare Policy. 2010 ; Vol. 5, No. 4. pp. 26-36.
@article{4f0d364a006b42de8d3a5618d33a54aa,
title = "Gardasil{\circledR} - The new HPV vaccine: The right product, the right time? A commentary",
abstract = "The federal and provincial governments have undertaken a universal immunization program to protect school-aged girls against cervical cancer using the new human papillomavirus vaccine Gardasil{\circledR}. While the vaccine appears to be effective and safe, there are a number of important unanswered questions regarding it and the effects of the immunization program. Here we briefly review key literature about the vaccine and then use the Erickson criteria, which offer an evidence basis for decision-making regarding national immunization strategies, to evaluate whether the program is congruent with sound public health policy. Our analysis of the national decision to recommend and fund a vaccination program using Gardasil{\circledR} raises significant questions about the basis for this program.",
author = "Joel Lexchin and Neil Arya and Sonal Singh",
year = "2010",
month = "5",
language = "English (US)",
volume = "5",
pages = "26--36",
journal = "Healthcare Policy",
issn = "1715-6572",
publisher = "Longwoods Publishing Corp.",
number = "4",

}

TY - JOUR

T1 - Gardasil® - The new HPV vaccine

T2 - The right product, the right time? A commentary

AU - Lexchin, Joel

AU - Arya, Neil

AU - Singh, Sonal

PY - 2010/5

Y1 - 2010/5

N2 - The federal and provincial governments have undertaken a universal immunization program to protect school-aged girls against cervical cancer using the new human papillomavirus vaccine Gardasil®. While the vaccine appears to be effective and safe, there are a number of important unanswered questions regarding it and the effects of the immunization program. Here we briefly review key literature about the vaccine and then use the Erickson criteria, which offer an evidence basis for decision-making regarding national immunization strategies, to evaluate whether the program is congruent with sound public health policy. Our analysis of the national decision to recommend and fund a vaccination program using Gardasil® raises significant questions about the basis for this program.

AB - The federal and provincial governments have undertaken a universal immunization program to protect school-aged girls against cervical cancer using the new human papillomavirus vaccine Gardasil®. While the vaccine appears to be effective and safe, there are a number of important unanswered questions regarding it and the effects of the immunization program. Here we briefly review key literature about the vaccine and then use the Erickson criteria, which offer an evidence basis for decision-making regarding national immunization strategies, to evaluate whether the program is congruent with sound public health policy. Our analysis of the national decision to recommend and fund a vaccination program using Gardasil® raises significant questions about the basis for this program.

UR - http://www.scopus.com/inward/record.url?scp=79851482181&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79851482181&partnerID=8YFLogxK

M3 - Article

C2 - 21532767

AN - SCOPUS:79851482181

VL - 5

SP - 26

EP - 36

JO - Healthcare Policy

JF - Healthcare Policy

SN - 1715-6572

IS - 4

ER -